PDL Biopharma Debt to Equity

PDL Biopharma posts a debt-to-equity ratio of 0.05. That is below the Healthcare sector average of 0.31. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

For Healthcare stocks, a debt-to-equity ratio near 0.31 is typical. PDL Biopharma's 0.05 is lower that level. That is roughly 85.1% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

PDL Biopharma's debt-to-equity ratio of 0.05 comes from dividing a price-based measure by a related financial statistic. Changes can come from the stock price moving, the underlying fundamental shifting, or both. Track both the level and the trend — a rising multiple on falling fundamentals is a different story than a rising multiple on rising earnings.

Context for PDLI's debt-to-equity ratio usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 0.31), and (3) consistency with growth and profitability. This page covers the first two; PDL Biopharma's other metric pages and overview cover the third.

Judging PDL Biopharma against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in debt-to-equity ratio easier to interpret. Start with 0.05 here, then scan peer and history charts to see if the gap is persistent.